How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.
BMRN - BioMarin Pharmaceutical Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$90.94
DETAILS
HIGH:
$124.00
LOW:
$59.00
MEDIAN:
$90.00
CONSENSUS:
$90.94
UPSIDE:
36.69%
Stock News
BioMarin to Participate in Upcoming Investor Conferences
Wells Fargo 21st Annual Healthcare Conference, September 9 at 3:00 pm EST Cantor Global Healthcare Conference 2026, September 10 at 10:20 am EST Citi's 2026 Biopharma Back to School Conference, September 10 at 1:00 pm EST Morgan Stanley 24th Annual Global Healthcare Conference, September 14 at 10:00 am EST SAN RAFAEL, Calif., Sept. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in September.
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
BioMarin Announces Close of the Alesta Therapeutics Acquisition
Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipeline SAN RAFAEL, Calif., Sept. 1, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Alesta Therapeutics.
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes
On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S (NASDAQ:ASND)to resolve all global patent disputes regarding the medication Yuviwel.
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
Agreement Resolves all Pending Patent-Related Proceedings Between BioMarin and Ascendis SAN RAFAEL, Calif., Aug. 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has entered into binding terms with Ascendis Pharma A/S, resolving the patent and ancillary disputes pending globally, including before the U.S. International Trade Commission (ITC) concerning Ascendis's Yuviwel.
Bank of New York Mellon Corp Makes New $66.11 Million Investment in BioMarin Pharmaceutical Inc. $BMRN
Bank of New York Mellon Corp bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,155,305 shares of the biotechnology company's stock, valued at
ADAR1 Capital Management LLC Acquires New Stake in BioMarin Pharmaceutical Inc. $BMRN
ADAR1 Capital Management LLC acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 49,000 shares of the biotechnology company's stock, valued at approximately $2,804,000. Other hedge funds and other
BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment
BMRN's $490M Alesta deal adds ALE1, a potential oral HPP therapy, broadening its rare bone disease portfolio and clinical pipeline.
BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment
BioMarin will acquire Alesta Therapeutics for $275 million upfront, and up to an additional $215 million based on milestones. Alesta Therapeutic's lead drug is a potential treatment for hypophosphatasia (HPP).
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Baidu, Ciena, CME Group, Dollar Tree, Dominion, Fabrinet, Honeywell Aerospace, Klarna, Pershing Square, and More
Markets turned south again Wednesday as surging yields and geopolitical fears rattled investors, but Wall Street analysts spotted opportunity and danger in names like Baidu, Klarna, Honeywell Aerospace, and Dollar Tree that traders need to see before the open.
BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
BioMarin to pay $275 million upfront, plus additional payments upon achievement of development and regulatory milestones Alesta to spin out all non-ALE1 assets to a new entity and Alesta employees to transfer to the spinout entity prior to close ALE1 has significant potential to help BioMarin expand into larger rare disease markets with a medicine intended to address a high unmet need for patients and offers strong strategic fit for the company SAN RAFAEL, Calif., Aug. 18, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that BioMarin has entered into a definitive agreement to acquire Alesta Therapeutics to gain Alesta's lead clinical-stage asset, ALE1.
Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?
Here is how BioMarin Pharmaceutical (BMRN) and Cardinal Health (CAH) have performed compared to their sector so far this year.
5 Undervalued Price-to-Book Stocks Worth Buying in August
BioMarin, Invesco, Centene, HPE and Gibraltar Industries stand out as undervalued stocks with low price-to-book ratios.
BMRN vs. ILMN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?
Wall Street Analysts See a 28.2% Upside in BioMarin (BMRN): Can the Stock Really Move This High?
The mean of analysts' price targets for BioMarin (BMRN) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth
BioMarin Pharmaceutical NASDAQ: BMRN outlined its growth strategy, integration plans for Amicus Therapeutics and pipeline priorities during a Canaccord discussion with Chief Financial Officer Brian Mueller.
Price Targets
BioMarin price target raised to $86 from $85 at Cantor Fitzgerald
$86.00
(was $65.31)
Cantor Fitzgerald
BioMarin price target raised to $90 from $88 at Piper Sandler
$90.00
(was $65.23)
Piper Sandler
BioMarin price target raised to $105 from $104 at Jefferies
$105.00
(was $65.53)
Akash Tewari
·
Jefferies
BioMarin price target raised to $109 from $105 at Raymond James
$109.00
(was $65.39)
Raymond James
Piper Sandler on BioMarin Pharmaceutical Inc. (BMRN): 'We Remain Bullish After Hosting Management Meetings'
$88.00
(was $66.10)
UBS
BioMarin initiated with an Outperform at BMO Capital
$98.00
(was $66.99)
David Lebowitz
·
BMO Capital
BioMarin price target lowered to $59 from $60 at H.C. Wainwright
$59.00
(was $67.79)
H.C. Wainwright
BioMarin price target raised to $88 from $82 at Piper Sandler
$88.00
(was $67.36)
Piper Sandler
BioMarin price target raised to $111 from $105 at Barclays
$111.00
(was $67.36)
Eliana Merle
·
Barclays
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at Canaccord
$114.00
(was $63.81)
Whitney Ijem
·
Canaccord Genuity
BioMarin price target raised to $105 from $100 at Raymond James
$105.00
(was $63.80)
Raymond James
BioMarin price target raised to $124 from $119 at Morgan Stanley
$124.00
(was $63.84)
Morgan Stanley
BioMarin price target raised to $70 from $68 at Stifel
$70.00
(was $63.55)
Stifel Nicolaus
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $97 at Oppenheimer
$97.00
(was $61.46)
Leland Gershell
·
Oppenheimer
BioMarin price target lowered to $62 from $66 at RBC Capital
$62.00
(was $58.79)
Luca Issi
·
RBC Capital
BioMarin price target lowered to $111 from $116 at Canaccord
$111.00
(was $54.10)
Canaccord Genuity
BioMarin price target lowered to $62 from $64 at Leerink
$62.00
(was $49.67)
Leerink Partners
BioMarin price target lowered to $50 from $55 at H.C. Wainwright
$50.00
(was $50.15)
H.C. Wainwright
BioMarin reinstated with a Neutral at Goldman Sachs
$69.00
(was $54.06)
Goldman Sachs
BioMarin price target raised to $120 from $110 at Evercore ISI
$120.00
(was $54.36)
Evercore ISI